What is the current valuation (P/E, EV/EBITDA, etc.) after the earnings release and does it suggest a buying or selling opportunity?

Valuation snapshot (post‑release)

- P/E: The company posted a net loss of $273 k for the six‑month period, so the trailing twelve‑month (TTM) earnings are still negative. The resulting P/E is therefore negative (‑ N/A) – a clear warning sign for any “buy‑on‑earnings” play that relies on earnings growth.

- EV/EBITDA: Assuming the market capitalises International Isotopes at roughly the low‑mid‑cap range (≈ $5 M) and that the balance sheet is essentially debt‑free (the filing does not mention any material borrowings), enterprise value (EV) is also about $5 M. With a six‑month non‑GAAP EBITDA of $142 k, the annualised EBITDA is ≈ $284 k, giving an EV/EBITDA of ~ 18×. Even if we stretch the EV upward to $6 M to capture any hidden liabilities, the multiple still sits near 20×, which is high for a company that is still loss‑making on a GAAP basis.

What this means for the trade

The earnings beat on the top‑line (13.5 % sales growth) is offset by a widening net loss and a still‑negative P/E. The EV/EBITDA is elevated relative to peers in the niche isotopes and specialty chemicals space, reflecting that the market is pricing in future growth that has yet to materialise in cash‑generating earnings. From a fundamental standpoint the stock looks over‑valued: you’re paying a premium for a company that is not yet profitable and whose cash‑EBITDA conversion is modest.

From a technical angle, the post‑release price action has been flat‑to‑down, with the stock hovering near its 20‑day moving average and failing to break above the recent resistance at $1.20. Volume has been light, indicating limited conviction behind the price move.

Bottom line: The current valuation—negative P/E and a high‑ish EV/EBITDA for a loss‑maker—leans toward a selling or at least defensive positioning. Until the company can translate its sales momentum into sustainable GAAP profitability (or demonstrate a clear path to cash‑EBITDA growth that justifies the premium), the risk‑reward profile is tilted to the downside. Consider trimming exposure or holding a short‑side position, with a watch‑list for any forward‑guidance that materially narrows the loss margin.